P57Kip2抗體 有絲分裂抑制因子

廣州健侖生物科技有限公司

p57Kip2 是一種細胞周期抑制因子，基因位于11p15.5，通過阻斷細胞周期中G1/S 期的轉(zhuǎn)換，實現(xiàn)對細胞周期的負調(diào)控，阻止細胞的增殖和腫瘤的形成。主要用于各種惡性腫瘤如星形細胞瘤等的研究。

我司還提供其它進口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢

P57Kip2抗體 有絲分裂抑制因子

【產(chǎn)品介紹】

細胞定位：細胞核

克隆號：KP10

同型：IgG

適用組織：石蠟/冰凍

陽性對照：胎盤

抗原修復(fù)：熱修復(fù)

抗體孵育時間：30-60min

P57Kip2抗體

想了解更多的產(chǎn)品及服務(wù)請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】     歐

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-103室

現(xiàn)在我們可以獲得攜帶正?；蚪M的無限增殖的人類抗原抗體上皮細胞，去探索細胞永生化的背后分子機制，我們也可以開始思考如何針對細胞永生化這一過程，防止或逆轉(zhuǎn)癌癥的發(fā)展。
干細胞(Stem Cells)被稱作人體組織細胞的自然蓄水池，擁有自我復(fù)制(自更新)和隨時分化成其它更專業(yè)化功能細胞的*能力，如此成為醫(yī)學(xué)科技人員治療一系列疾病和人體組織損傷強有力的技術(shù)工具。然而干細胞研究并非沒有爭論，特別是胚胎干細胞研究，已在科技界以及更廣泛的社會各界引發(fā)爭議。
歐盟干細胞研究正處于勃勃生機的“開花結(jié)果”階段，盡管部分研究仍處于前沿的科學(xué)探索，但系列的主要研究活動已轉(zhuǎn)向應(yīng)用研究或商業(yè)化應(yīng)用開發(fā)前期。例如，通過觀察控制干細胞，歐盟科技人員已實現(xiàn)準確的干細胞專業(yè)化功能開發(fā)，可廣泛應(yīng)用于治療重大疾病，如癌癥或細胞異常分裂與分化引發(fā)的先天性缺陷疾病。

Now we can get the immortalized human antigen antibody epithelial cells carrying the normal genome to explore the underlying molecular mechanism of cell immortalization and we can also start to think about how to deal with the immortalization of cells and prevent or reverse the development of cancer.
Stem Cells, known as natural reservoirs of human tissue cells, have the unique ability to self-replicate (self-renew) and readily differentiate into other more specialized functional cells, thus becoming a medical technologist for the treatment of a range of diseases and human tissues Damage powerful technical tools. However, stem cell research is not without controversy. In particular, research on embryonic stem cells has caused controversy in the scientific and technological community as well as in the wider community.
The EU stem cell research is in the midst of an "inflorescence" stage of vitality. Although some of the studies are still at the cutting edge of scientific exploration, the major research activities of the series have shifted to the early stages of applied research or commercial application development. For example, through the observation and control of stem cells, EU scientists and technologists have developed accurate stem cell specialized functions and are widely used in the treatment of major diseases such as cancer or congenital defects caused by abnormal cell division and differentiation.